

**Direct Import**

**REBLOZYL<sup>®</sup>**  
(luspatercept)

# Patient Card

Important Safety Information for Women of Childbearing Potential

## Ireland Version 1.0

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects and/or pregnancies directly via HPRC Pharmacovigilance at [www.hpra.ie](http://www.hpra.ie). By reporting side effects you can help provide more information on the safety of this medicine. Side effects and/or pregnancies can also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or [medical.information@bms.com](mailto:medical.information@bms.com).

This material fulfils the conditions of the marketing authorisation for luspatercept and has been approved by the Health Products Regulatory Authority (HPRA).

# Patient Information

Luspatercept may cause harm to your unborn baby.

- Luspatercept should not be used during pregnancy and for at least 3 months before getting pregnant.
- Do not use luspatercept if you are pregnant, or could become pregnant and are not using at least one highly effective method of contraception.
- Do not breastfeed whilst using this medicine and for 3 months after your last dose of luspatercept.

## **Before starting treatment with luspatercept:**

- You must have a negative pregnancy test verified by your prescriber.
- Talk to your doctor about methods of contraception that may be suitable for you. You must use at least one highly effective method of contraception during treatment with luspatercept and for at least 3 months after your last dose of luspatercept.

## During Treatment:

- A pregnancy test must be repeated at suitable intervals.
- Tell your doctor right away if you are pregnant or think you might be pregnant during treatment with luspatercept and for 3 months after stopping luspatercept.
- You must use at least one highly effective method of contraception during treatment with luspatercept and for at least 3 months after your last dose of luspatercept.

For more information, please refer to the Package Leaflet for luspatercept. The Package Leaflet is available to view or download from the 'Product Information' section at <https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl>. You can also telephone Bristol-Myers Squibb Medical Information on 1 800 749 749 or email [medical.information@bms.com](mailto:medical.information@bms.com).

Please complete this section or ask your prescriber of Iuspatercept to complete it.

Name of Doctor:

Office Phone number:

Address of Doctor:

2007-GB-2400003

Date of Preparation: March 2025

Date of HPRA Approval: March 2025